InvestorsHub Logo
Followers 219
Posts 15975
Boards Moderated 7
Alias Born 06/02/2007

Re: Longpicker post# 341534

Tuesday, 01/26/2021 5:15:45 AM

Tuesday, January 26, 2021 5:15:45 AM

Post# of 403002
"Laboratory testing has shown the drug to be 97% effective in killing the Sars Cov 2 virus while maintaining a very high safety profile."

Laboratory testing - by which I assume from the context you mean in vitro testing - tells us little or nothing about the safety profile of a drug in vivo.

In reality we know from the limited information released from Phase II studies that even topically applied brilacidin is associated with some serious adverse events (see here, for example: https://clinicaltrials.gov/ct2/show/results/NCT02324335?term=brilacidin&draw=2&rank=1).

I suspect a full tabulation of the Adverse Events associated with brilacidin in all the human studies to date would be surprising to those who claim (in the face of the already available evidence to the contrary) that brilacidin is completely safe.

I also suspect that's one of the reasons that a deep-pocketed pharma company hasn't already snapped up what otherwise, from the little information in the public domain, looks like a very promising candidate.

If brilacidin were all Ehrlich claims, then there's any number of companies who would pay hundreds of millions upfront with more hundreds of millions in milestones.

Why haven't they?

"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

"Nobody ever went broke underestimating the intelligence of the American public."

H. L. Mencken

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News